Aim Lymphoma Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aim Lymphoma Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aim Lymphoma Study Today - Breaking & Trending Today

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Published: July 6, 2023

/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...

Source: prnewswire.com

Related Topics:

James DentzerClinical Development Of CurisCuris IncDrug AdministrationPrnewswire Curis IncRoche GroupTakeaim Leukemia PhaseAcute Myelogenous LeukemiaMyelodysplastic SyndromesTakeaim LeukemiaChief Executive OfficerComplete ResponsePartial Hematologic RecoverySenior Vice PresidentClinical DevelopmentAim Leukemia StudyAim Lymphoma StudyAim LymphomaAim LeukemiaOrphan Drug Designation